Comparative Pharmacology
Head-to-head clinical analysis: TOVALT ODT versus ZYPREXA ZYDIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOVALT ODT versus ZYPREXA ZYDIS.
TOVALT ODT vs ZYPREXA ZYDIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tovalt ODT (selegiline) is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). At therapeutic doses, it inhibits MAO-B more selectively than MAO-A, leading to increased levels of dopamine in the brain.
Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C receptors, dopamine D1-D4 receptors, muscarinic M1-M5 receptors, histamine H1 receptors, and alpha1-adrenergic receptors. Antagonism at D2 and 5-HT2A receptors is primarily responsible for its antipsychotic effects.
20 mg sublingually as needed for BTP, with a minimum interval of 2 hours between doses; maximum 4 doses per day.
10 mg orally once daily; range 5-20 mg once daily. Initial dose 5-10 mg, titrate by 5 mg weekly. Maximum 20 mg/day. Orally disintegrating tablet.
None Documented
None Documented
Terminal elimination half-life approximately 40–60 hours after multiple dosing; clinical context: reaches steady-state after 2–3 weeks.
Terminal elimination half-life: ~30 hours (range 21–54 hours) in healthy adults; prolonged in elderly (mean 51.8 h) and hepatic impairment.
Primarily hepatic metabolism; 70–80% as inactive metabolites in urine, <5% unchanged in urine, 20–30% fecal.
Renal: ~57% (as metabolites); Fecal: ~30% (as metabolites); Unchanged olanzapine in urine <7%.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic